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Abstract
Background: To assess changes in the treatment of hypercholesterolemia in Polish ambulatory care 
over the last 6 years.
Methods: Data were obtained from two separate questionnaire-based studies, conducted in 2009 and 
2015. The analysis included only those patient visits, which were associated with modifications of previ-
ous hypercholesterolemia treatment (1924 visits from the year 2009 and 1888 visits from the year 2015). 
Results: In the present registry, there was a 19 mg/dL reduction in the level of total cholesterol and  
a 17 mg/dL reduction in the level of low-density lipoprotein compared to year 2009. In both registries, the 
most common reason for treatment modification was failure to achieve therapeutic goals. Compared to 
year 2009, there was an increase in the proportion of patients treated with atorvastatin and a reduction 
in the proportion of patients treated with simvastatin at baseline; additionally, in year 2015, 10% of 
patients received rosuvastatin. After therapy modification, there was a similar increase in the proportion 
of patients treated with a statin-fibrate combination in both registries. However, at present, ezetimibe 
was significantly less often added to previous therapy. In both registries, therapy modification led to an 
increase in the mean doses of the most commonly used statins, although presently, this increase was 
smaller than in 2009. 
Conclusions: The most favorable change in the treatment of hypercholesterolemia is an increase in 
the proportion of patients treated with strong statins. Unfavorable changes include a reduction in the 
frequency of polytherapy, especially with ezetimibe, and a tendency to prescribe lower, ineffective statin 
doses. (Cardiol J 2017; 24, 3: 266–275)
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Introduction
According to the European Society of Cardiol-
ogy (ESC), hypercholesterolemia is defined as total 
cholesterol concentration of above 190 mg/dL and/ 
/or low-density lipoprotein (LDL) concentration 
of above 115 mg/dL [1]. Hypercholesterolemia is 
among the most important and at the same time, 
the most common risk factors of atherosclerosis, 
prevalent in 18 million (61%) adults in Poland 
[2, 3]. Clinical trials and meta-analyses have un-
equivocally demonstrated that cardiovascular risk 
constantly decreases with decreasing LDL con-
centrations, and that every reduction of 40 mg/ 
/dL in LDL concentration results in a 20%-reduction 
in cardiovascular morbidity and mortality [4]. This 
observation has led to a gradual reduction in target 
LDL concentration in patients treated for hypercho-
lesterolemia over the last few years [5–8]. Another 
important trend in hypercholesterolemia treatment 
is a constant, progressive individualization of thera-
peutic goals. According to the ESC guidelines, target 
LDL concentration should be based on an individual 
assessment of total cardiovascular risk [6–8].
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The aim of the study was to evaluate changes 
in the treatment of hypercholesterolemia in Polish 
cardiologic ambulatory care over the last 6 years.
Methods
The current analysis was based on the results 
of two, separate questionnaire studies, conducted 
almost 6 years apart (i.e. between August and 
September 2009, and between January and March 
2015). In each of these studies, 130 cardiologists 
participated, who had been professionally active for 
from 2 to 30 years, had treated at least 80 hyper-
cholesterolemia patients monthly and worked in 
cardiologic ambulatory care in provincial cities or 
other cities with the greatest number of cardiolo-
gists (maintaining the proportion in the number of 
cardiologists working in provincial and non-provin-
cial cities; random quota selection). Table 1 shows 
the number of cardiologists participating in the 
2009 and the 2015 registry in relation to city type 
and size. Table 2 presents numbers of participating 
cardiologists and patients in relation to Poland’s 
provinces. Out of the 16 provinces in Poland, only 
one (Lubusz) was not involved in these surveys. 
Out of 130 cardiologists engaged in the study in 
year 2015, 39 (30%) had previously participated in 
the 2009 registry. In year 2009, there were 88 sites 
participating in the survey. In the 2015 registry, 
120 sites were involved, including 25 (21%) sites 
which had participated in the 2009 survey.
Both registries included only those patient 
visits which were associated with modifications 
of previous hypercholesterolemia treatment and 
which satisfied at least one of the following condi-
tions: addition of another hypolipidemic agent, 
cessation of hitherto used hypolipidemic therapy, 
replacement of previously used hypolipidemic 
drug and/or changes in dosing of a hypolipidemic 
agent. Every participating cardiologist was asked 
to include 15 consecutive visits that fulfilled those 
conditions. 
Both studies were conducted by an independ-
ent research company Sequence HC Partners and 
funded from research grants of MSD Poland. Sci-
entific description and interpretation of the results 
was conducted in the 1st Chair and Department of 
Cardiology, Medical University of Warsaw, Poland.
Statistical analysis 
Qualitative variables are presented as relative 
frequencies. Quantitative variables are presented 
as a mean value ± standard deviation (SD). The 
z-test for two independent proportions was used 
to determine statistical significance of differ-
ences between the 2009 and the 2015 population. 
P-values of < 0.05 were considered significant. 
Some portion of data obtained from both registries 
has been presented in previous publications [9–11].
Results
Comparison of clinical characteristics  
of both study populations
A total of 1924 visits were included in the 2009 
registry, and 1888 visits in the 2015 registry. Clini-
cal characteristics of both populations have been 
presented in previous publications [9–11]. Table 3 
presents a comparison of clinical characteristics of 
the two populations. 
Achievement of lipid therapeutic goals  
in both registries
In comparison to the 2009 population, in the 
2015 registry the following observations were 
recorded: a reduction of mean total cholesterol 
concentration by 19 mg/dL, of mean LDL con-
centration by 17 mg/dL and of mean triglyceride 
concentration by 13 mg/dL, as well as an increase 
in mean high-density lipoprotein (HDL) concen-
tration by 4 mg/dL (p < 0.05 for all differences) 
(Fig. 1). In year 2015, a proportion of patients who 
achieved an LDL concentration below 100 mg/dL 
more than doubled (from 12% to 27%, p < 0.05) 
Table 1. Number of cardiologists participating in 
the 2009 and the 2015 registry in relation to city 
type and city size. 
No. of participating  
cardiologists
2009  
registry
2015  
registry
City type
Provincial* 106 88
Non-provincial** 24 42
Total 130 130
City size (population) 
< 100,000 22 31
100,000–200,000 16 23
200,000–500,000 37 30
> 500,000 55 46
Total 130 130
*Provincial city, i.e. a capital of a province
**Non-provincial city, i.e. a city or town which is not a capital  
of a province
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Table 2. Number of cardiologists and patients participating in the 2009 and the 2015 registry in relation 
to provinces. 
Province 2009 registry 2015 registry
Number of  
cardiologists
Number of  
patients
Number of  
cardiologists
Number of  
patients
Lower Silesian 11 165 12 166
Kuyavian-Pomeranian 8 120 8 118
Lublin 4 56 4 59
Lodz 6 90 6 90
Lesser Poland 11 165 11 158
Masovian 31 460 24 348
Opole 2 27 1 10
Podkarpackie 3 45 4 60
Podlaskie 3 45 2 30
Pomeranian 7 105 8 120
Silesian 20 292 20 290
Swietokrzyskie 2 30 3 45
Warmian-Masurian 4 58 3 45
Greater Poland 12 176 16 231
West Pomeranian 6 90 8 118
Total 130 1924 130 1888
Table 3. Clinical characteristics of the studied populations. 
2009 registry  
(n = 1924)
2015 registry  
(n = 1888)
P
Age [years] 63.0 ± 10.4 63.5 ± 11.2 NS
Women 47% 44% < 0.05
Body mass index [kg/m2] 28.5 ± 4.9 28.5 ± 4.9 NS
Obesity 40% 34% < 0.05
Duration of hypercholesterolemia treatment [years] 4.4 ± 4.3 6.6 ± 4.7 < 0.05
Familial hypercholesterolemia* 25% 17% < 0.05
Arterial hypertension 86% 89% < 0.05
Coronary artery disease 68% 57% < 0.05
Previous acute coronary syndrome 47% 36% < 0.05
Previous coronary revascularization 32% 28% < 0.05
Chronic heart failure 21% 17% < 0.05
Previous cerebral stroke 11% 8% < 0.05
Peripheral artery disease 16% 13% < 0.05
Type 2 diabetes 34% 33% NS
Smoking 42% 38% < 0.05
Primary prevention 28% 34% < 0.05
Secondary prevention** 72% 66% < 0.05
*Diagnosis made at the discretion of participating cardiologists 
**I.e. patients with a history of coronary artery disease, cerebral stroke or peripheral artery disease; NS — non-significant (i.e. p ≥ 0.05)
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[9–11]. The proportion of patients with an LDL 
concentration below 70 mg/dL had also significantly 
increased (from 2% in the 2009 registry to 10% in 
the 2015 registry, p < 0.05). Moreover, the time 
between consecutive lipid testing was significantly 
shorter in 2015, with mean time from the last total 
cholesterol testing shorter by 31 days, mean time 
from the last LDL cholesterol testing — by 30 
days, mean time from the last HDL cholesterol 
testing — by 38 days, and mean time from the last 
triglyceride testing shorter by 36 days in 2015 as 
compared to 2009 (p < 0.05 for all differences).
Baseline hypercholesterolemia treatment 
in both registries
Figure 2 demonstrates baseline hypolipidemic 
treatment in years 2009 and 2015. While comparing 
baseline statin treatment in both registries, one 
should note a reversal in the proportion of patients 
treated with simvastatin and atorvastatin (with 
simvastatin used in 62% of patients in 2009, and 
in 30% of patients in 2015, and atorvastatin used 
in 31% of patients in 2009, and in 56% of patients 
in 2015), as well as an introduction of rosuvasta-
tin (registered in year 2009 and not yet used in 
Figure 1. Mean concentrations of total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) 
and triglycerides (TG) in the 2009 and 2015 registry (based on [9–11], modified).
Figure 2. Pharmacotherapy of hypercholesterolemia before modification in the 2009 and 2015 registry (based on 
[9–11], modified).
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patients from the 2009 registry), which was given 
to 10% of patients in year 2015 (p < 0.05 for all 
differences) [9–11]. The frequency of treatment 
with other statins (i.e. pravastatin, fluvastatin and 
lovastatin) was negligible in both registries.
In the 2015 survey, less patients were treated 
with fibrates compared to the 2009 registry (9% 
vs. 13%, respectively, p < 0.05). In both registries, 
the most commonly used fibrate was fenofibrate, 
which was given to 10% of the whole study group 
in 2009 and to 8% of the whole study group in 2015 
(p-value non-significant); other patients received 
ciprofibrate. 
Hypercholesterolemia treatment after 
therapy modification in both registries
In both registries, the most common reason 
for therapy modification was failure to achieve 
therapeutic goals (in 84% patients in 2009 and 
in 75% patients in 2015, p < 0.05). Compared to 
the previous registry, in year 2015, other reasons 
for therapy modification significantly more often 
included: fear of future adverse effects (11% vs. 
9% in 2009, p < 0.05), statin intolerance (6% vs. 
4% in 2009, p < 0.05) and achievement of thera-
peutic goal (8% vs. 2% in 2009, p < 0.05). On the 
other hand, adverse effects were less common in 
year 2015 than in year 2009 (5% in 2015 vs. 7% in 
2009, p < 0.05).
Figure 3 shows hypolipidemic treatment after 
therapy modification in the 2009 and 2015 regis-
tries. In both registries, the most common type 
of modification was a change (most often — an 
increase) in statin dose and a replacement of one 
statin with another — these two modifications were 
more often introduced (by 12%) in year 2015 in 
contrast with 2009. Compared to the 2009 registry, 
in year 2015, ezetimibe was significantly less often 
added to the hitherto therapy: in 2009 ezetimibe 
was added in 16% of cases, which was the third 
most common type of therapy modification, while 
in 2015 ezetimibe was added only in 5% of cases 
(p < 0.05). On the other hand, fibrates were added 
to therapy with a similar frequency in both regis-
tries (in 12% and in 11% of patients in year 2009 
and 2015, respectively, p-value non-significant).
In both registries, therapy modification re-
sulted in a reduction in the proportion of patients 
treated with simvastatin (down to 37% in year 
2009, and down to 9% in year 2015).  An increase 
in the proportion of patients receiving atorvastatin 
was also noted (up to 57% in 2009 and up to 62% 
in 2015). Additionally, in year 2015, after therapy 
modification, there was a further increase in the 
frequency of rosuvastatin treatment (up to 25%) 
[9–11].
In both registries, among the patients who, 
after therapy modification, were using the same 
statin molecule, its dose was increased in more 
than a half of them (in 55% in 2009 and in 57% 
in 2015). However, compared to year 2009, in 
year 2015, cardiologists more often reduced the 
dose of hitherto used statin (in 16% in 2009 and 
in 25% in 2015, p < 0.05). In both registries, the 
most common type of dosing modification, for both 
simvastatin and atorvastatin, was an increase from 
a dose of 20 mg per day to a dose of 40 mg per day. 
After therapy modification, the most frequently 
Figure 3. Pharmacotherapy of hypercholesterolemia after modification in the 2009 and 2015 registry (based on [9–11], 
modified).
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used atorvastatin dose in both registries was 
a dose of 40 mg daily, which was prescribed to 60% 
of atorvastatin-treated patients in 2009, and in 47% 
of atorvastatin-treated patients in year 2015. Ator-
vastatin 80 mg daily was rarely prescribed in both 
registries, with only 18 patients (0.9% of the whole 
study group; 3% of atorvastatin-treated patients) 
at baseline, and 45 patients (2% of the whole study 
group; 4% of atorvastatin-treated patients) after 
treatment modification in year 2009. In the 2015 
registry, only 40 patients (2% of the whole study 
group; 4% of atorvastatin-treated patients) were on 
atorvastatin 80 mg daily at baseline, and 70 patients 
(4% of the whole study group; 6% of atorvastatin-
treated patients) were on atorvastatin 80 mg after 
treatment modification. For simvastatin, the most 
frequently prescribed dose after therapy modifica-
tion was a dose of 40 mg daily in year 2009 (55% 
of simvastatin-treated patients), and 20 mg daily 
in year 2015 (42% of simvastatin-treated patients). 
After therapy modification, mean atorvastatin dose 
increased by 7.9 mg daily (up to 34.4 mg daily) in 
year 2009, and by 5.6 mg daily (up to 33.3 mg daily) 
in year 2015; mean simvastatin dose increased by 
8.7 mg daily (up to 32.4 mg daily) in 2009, and only 
by 3.4 mg daily (up to 26.0 mg daily) in 2015; mean 
rosuvastatin dose increased in 2015 by 3.9 mg daily 
(up to 21.6 mg daily).
In year 2009, therapy modification resulted 
in an increase in the frequency of fenofibrate use, 
as it was prescribed to 17.5% of the whole studied 
group (among 18% fibrate-treated patients) and 
in a reduction in the frequency of ciprofibrate use 
(from 2.4% to 0.5% of the whole group). However, 
mean fenofibrate dose decreased from 217 mg to 
208 mg daily. Similarly, in year 2015, most of the 
fibrate-treated patients received fenofibrate (after 
therapy modification, ciprofibrate was used only 
in 0.7% of the whole group studied). No data on 
fibrate dosing before and after therapy modification 
in 2015 were obtained.
In both registries, mean ezetimibe dose was 
10 mg daily (both before and after therapy modi-
fication). 
Discussion
The analyzed data were obtained during two 
questionnaire-based surveys conducted among 
cardiologists working in ambulatory care. Criteria 
for selection of participating cardiologists, inclusion 
criteria for patient visits, as well as the type and 
scope of gathered data were the same in 2009 and 
in 2015, which enabled a direct comparison of the 
results [9–11]. Thus, it may be assumed that the 
presented data adequately reflect recent changes 
in hypercholesterolemia treatment in cardiologic 
ambulatory care in Poland. 
In order to interpret these data correctly, one 
must take into account that both the 2009 and 
the 2015 registry included patients in whom, for 
various reasons (most frequently due to failure 
to achieve therapeutic goals), there was a need 
for hypolipidemic treatment modification, most 
frequently for intensification. Thus, the studied 
groups are not representative for the whole popu-
lation of Polish adults treated for hypercholester-
olemia in ambulatory care.
Compared to the 2009 population, patients 
included in the 2015 registry had, despite being 
the same age, had lower cardiovascular risk, which 
might, on one hand, imply some minor improve-
ment in general health condition in this age group, 
(although due to the relatively small size of the 
studied group and particular study inclusion criteria 
these results cannot be extrapolated to the whole 
Polish population), and, on the other hand, it may 
demonstrate a tendency for a more timely referral 
of patients burdened with cardiac risk factors to 
specialist cardiologic care, even before they de-
velop clinically overt cardiovascular disease, such 
as coronary artery disease or chronic heart failure. 
Compared to the population studied in year 
2009, patients in whom hypolipidemic therapy 
was modified in 2015 were characterized by a bet-
ter lipid control. This is probably predominantly 
due to the changes in the 2011 ESC guidelines on 
dyslipidemias which, compared to the previous 
guidelines, have decreased target LDL concentra-
tions in patients with high and very high cardio-
vascular risk and changed the definition of high 
and very high risk patients including new patient 
subgroups (e.g. patients with chronic kidney dis-
ease or subjects with high risk of cardiovascular 
death according to the SCORE chart) into these 
groups [5, 6]. The differences in baseline LDL 
concentration between year 2009 and 2015 reflect 
the tendency of attending cardiologists to intensify 
hypolipidemic treatment at an earlier stage. Other 
potential factors that might have contributed to the 
observed differences in LDL levels between the 
two registries could also include: a more timely 
referral of patients burdened with cardiac risk fac-
tors to specialized cardiologic care by general prac-
titioners (GPs) (e.g. due to increasing awareness 
of the importance of LDL control among both GPs 
and patients themselves, or due to changes in the 
healthcare system), more intensive lipid-lowering 
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treatment, including both life-style modifications 
and pharmacotherapy, socio-economic fluctuations, 
or even, though it remains to be tested, changes in 
LDL concentration on the population level.
Another favorable change, compared to year 
2009, is the observed reduction in time period be-
tween consecutive lipid testing — in the 2015 report 
its length was approximately 2 months, which is in 
line with both the 2011 and the current, 2016 ESC 
guidelines (according to the guidelines after therapy 
initiation or modification, subsequent lipid testing 
should be performed after 8 ± 4 weeks) [6, 7, 11].
Despite favorable changes in the lipid profile 
of patients in whom hypolipidemic therapy was 
modified in year 2015, the obtained mean LDL 
cholesterol level of 129 mg/dL is still significantly 
above the target concentration even for the low 
and moderate cardiovascular risk groups (< 115 
mg/dL), whereas more than a half of the analyzed 
population included patients with very high total 
cardiovascular risk, for whom the target LDL level 
is below 70 mg/dL [6, 7, 11].
An unfavorable change, compared to the 2009 
data, is a significant reduction in the frequency 
of combination therapy (especially with statin 
and ezetimibe) in the hypolipidemic treatment 
of patients who did not reach their therapeutic 
goals. Whereas the initial proportion of patients 
on combination therapy was similar in both reg-
istries (9% in year 2009 and 7% in year 2015), 
the proportion of patients on combination therapy 
after treatment modification increased to 29% in 
year 2009, and only to 18% in year 2015. This 
difference was mainly due to the fact, that in year 
2015 ezetimibe was more than 3 times less often 
added to therapy than in year 2009 (fibrates — 
mainly fenofibrate — were added to treatment 
with a similar frequency in both registries). As 
a result, in year 2009, after therapy modification, the 
number of patients treated with a statin-ezetimibe 
combination (14%) was equal to the number of 
patients treated with a statin-fibrate combination 
(14%), with a total proportion of patients treated 
with ezetimibe in monotherapy or in combination 
therapy as high as 17%. In year 2015, a statin-
ezetimibe combination was prescribed over 3 times 
less often than a statin-fibrate combination (i.e. 
only in 4% of patients), with a total proportion of 
patients treated with ezetimibe, in monotherapy 
or in combination therapy, being as low as 6%. 
A triple combination of statin, ezetimibe and fibrate 
was rarely prescribed in both registries.
Thus, in year 2015, the choice of hypolipidemic 
drugs added to statins in patients who did not 
reach their therapeutic goals was, in fact, limited 
to fenofibrate. Such a drastic reduction in the fre-
quency of ezetimibe use might be explained by the 
disadvantageous results of the ENHANCE study, 
which showed no difference in carotid intima–me-
dia thickness with combined simvastatin-ezetimibe 
therapy compared with simvastatin alone, despite 
greater reductions in C-reactive protein and LDL 
concentrations on ezetimibe [12]. The results 
of the ENHANCE trial, published in 2008, could 
have triggered a progressive reduction in the 
prescription of ezetimibe, which might not have 
been entirely evident by 2009, but has probably 
continued thereafter.
The observed reduction in ezetimibe use in our 
study should be considered unfavorable, especially 
in the context of the recently published results of 
the IMPROVE-IT trial, which has demonstrated 
an advantage of a simvastatin-ezetimibe combina-
tion therapy over simvastatin monotherapy, i.e. 
a reduction in the risk of a combined clinical endpoint 
(cardiovascular death, myocardial infarction, unsta-
ble angina, need for coronary revascularization and 
ischemic stroke) in patients after acute coronary 
syndromes [13]. However, our second survey was 
conducted at the beginning of year 2015, prior to 
the publication of the results of the IMPROVE-IT 
trial late in 2015. Thus, another increase in the 
frequency of ezetimibe use might be anticipated 
in 2016 and in years to come.
Given no reduction in cardiovascular outcomes 
with fenofibrate in the ACCORD trial, published in 
2010, as well as lower mean triglyceride concentra-
tion in the 2015 registry, a reduction in fibrate use 
in 2015 as compared to 2009 was to be anticipated 
[14]. Indeed, at baseline less patients were treated 
with fibrates in the 2015 registry compared to the 
2009 survey. However, surprisingly, the proportion 
of patients in whom fibrates were added to previous 
therapy during the index visit did not significantly 
decrease. It could be hypothesized that a similar 
proportion of patients who were prescribed fi-
brates during the index visit in the 2009 and the 
2015 registry might be related to: 1) the fact that 
no clear benefit of fenofibrate therapy seen in the 
ACCORD trial (2010) was concordant with the 
results of the previous FIELD study (2005); 2) the 
fact that fibrates remain the most effective agents 
lowering triglyceride concentrations, (and in both 
registries approximately one quarter of patients 
had a triglyceride level of above 200 mg/dL despite 
hitherto hypolipidemic treatment) — although it 
needs to be emphasized that in patients at high 
cardiovascular risk with moderately elevated 
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triglyceride levels, statins (especially more po-
tent statins, such as atorvastatin or rosuvastatin) 
should be the first drugs of choice, as they reduce 
both triglyceride concentration and cardiovascular 
mortality [6, 7, 14, 15].
A beneficial tendency, observed in the 2015 
registry, is an increase in the use of “strong” 
statins (atorvastatin, rosuvastatin) at the expense 
of “weaker” statins. In year 2009, simvastatin was 
initially given to almost two-thirds of all patients, 
and atorvastatin — to less than one third. Therapy 
modification in year 2009 led to a reversal of these 
proportions. In year 2015, an initial proportion of 
simvastatin–atorvastatin use was already similar to 
the proportion observed after therapy modification 
in year 2009, and modification of treatment in 2015 
resulted in a further increase in the frequency of 
atorvastatin use, at the expense of simvastatin. Ad-
ditionally, in year 2015, rosuvastatin was given to 
one tenth of patients at baseline, and after therapy 
modification, to as many as a quarter of patients. On 
the other hand, statins were given in suboptimal 
doses — and thus, although atorvastatin is preva-
lently prescribed more frequently than 6 years ago, 
its mean dose and mean increase in its dose after 
therapy modification were lower than in year 2009. 
It is also clearly visible that in year 2015, doctors 
tended to avoid high doses of simvastatin, which 
might be explained by the negative opinion of the 
American Food and Drug Administration (FDA) 
on its use in high doses (published in year 2011), 
especially if we take into account that the fear of 
future adverse effects was the reason for therapy 
modification in one tenth of cases [16]. However, 
given the unsatisfactory lipid control in the study 
group it seems difficult to understand, why this 
situation resulted, in some of the patients, in con-
tinuation of simvastatin in a lower dose, instead of 
replacing it with a stronger statin.
Compared to the 2009 registry, in year 2015, 
statin dose was more frequently reduced. In year 
2015, statin dose was reduced in as many as a quar-
ter of all patients, even though statin intolerance 
was reported in only 6% of cases. In year 2015, it 
was also more common than in year 2009 to modify 
therapy due to fear of adverse events, despite the 
fact that their actual frequency had decreased. Fur-
thermore, in year 2015, therapy modification was 
also more often reported to be due to the “achieve-
ment of a therapeutic goal” — a situation which 
should rather lead to continuation of the previous, 
successful pharmacotherapy. The recently growing 
fear for adverse effects of statins could have been 
a result of an FDA warning (published in 2012) on 
the increased risk of type 2 diabetes development 
in statin-treated patients [17]. Although clinical 
studies and meta-analyses conducted so far have 
confirmed the existence of this relationship, the 
effect of statin therapy on glucose homeostasis 
seems relatively minor — in non-diabetic patients 
treated with statins fasting glycemia is on average 
only 3 mg/dL higher than in subjects not receiving 
these drugs, and in diabetic patients statin use is 
associated with an increase in the proportion of 
glycated hemoglobin (HbA1c) by 0.12% compared to 
diabetics not treated with statins [18–20]. Although 
the results of a recently published METSIM study 
suggest that the risk of type 2 diabetes development 
on statin therapy might be higher than previously 
anticipated, still, the undeniable benefits of statin 
use in patients with high or very high total cardio-
vascular risk overweight the potential risk of their 
adverse effects [21].
Apart from the present analysis, there is 
a considerable lack of data on current trends in 
hypolipidemic therapy in Poland. The largest study 
recently that analyzed hypolipidemic treatment 
in Polish outpatients was the 3ST-POL study 
published in 2013 [22]. However, it specifically 
focused on statin therapy only. The 3ST-POL study 
included 49,950 Polish ambulatory patients receiv-
ing statins. The most frequently used statins were 
atorvastatin (49% of patients) and simvastatin 
(45%), which is consistent with the trend observed 
in our registries, with a growing proportion of 
patients receiving atorvastatin (from 31% in 2009 
to 56% in 2015) and a decreasing proportion of 
patients on simvastatin (from 62% in 2009 to 30% 
in 2015). The most commonly prescribed dosage 
for both statins in the 3ST-POL study was 20 mg 
daily, which is similar to what was observed in both 
our registries before therapy modification. High-
-risk patients accounted for 72% of all 3ST-POL 
patients. Their mean total cholesterol (245 mg/dL) 
and LDL cholesterol concentrations (143 mg/dL) 
were comparable to the levels observed in the 2009 
registry, though higher than in the 2015 survey. 
This may be attributable to the fact that, contrary 
to the present analyses, in the 3ST-POL study, 
79% patients were treated by GPs and only 16% 
by cardiologists. Of note, patients under specialist 
care more often reached target total cholesterol 
level as compared to patients treated by GPs [22].
In the Polish cohort of the EUROASPIRE III 
survey (2006–2007), mean total and LDL choles-
terol concentrations at ambulatory visit (at least 
6 months after a coronary event) were signifi-
cantly lower than in both registries (162 mg/dL and 
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89 mg/dL, respectively) with 93% of patients 
on statin therapy [23]. This may reflect the fact 
that the EUROASPIRE survey was conducted in 
reference cardiac centers and thus encompassed 
a selected population, not necessarily representa-
tive of the majority of Polish patients treated for 
hypercholesterolemia. An analysis of the Polish 
subgroup of the latest EUROASPIRE IV survey 
has as yet not been published [24]. 
Limitations of the study
Both registries in this study included only 
visits associated with modifications of previous 
hypolipidemic therapy. Furthermore, only 21% of 
sites and 30% of cardiologists involved in the 2015 
survey, had previously participated in the 2009 
registry. Despite the fact that all but one of Poland’s 
provinces were included in the surveys, as well as 
an attempt to maintain proportions in the number of 
cardiologists working in provincial (i.e. capitals of 
provinces) and non-provincial (i.e. other than pro-
vincial) cities similar to that observed in the whole 
country, it needs to be emphasized that the results 
of the study cannot be considered representative 
for the whole population of Polish adults treated for 
hypercholesterolemia in ambulatory care.
The diagnosis of familial hypercholesterolemia 
was made at the discretion of the participating 
cardiologists (“yes” vs. “no” in the registry ques-
tionnaires) and was not objectively verified by the 
investigators, resulting in an unexpectedly high 
proportion of this diagnosis in both registries.
Conclusions
Among the changes observed in the treatment 
of hypercholesterolemia over the last 6 years, ben-
eficial ones include an increase in the use of more 
potent statins (atorvastatin, rosuvastatin), achieve-
ment of lower total cholesterol and LDL concentra-
tions, even in the population with suboptimal lipid 
control, and reduction of time between consecutive 
lipid testing. Unfavorable changes include a signifi-
cant reduction in the use of combination therapy, 
especially with ezetimibe, in patients who did not 
reach their therapeutic goals and a tendency to 
prescribe lower, suboptimal statin doses.
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